Drugs / PIC1 Injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07456371 | Mar → Dec 2026 expected | non-Hodgkin lymphoma | Chongqing Precision Biotech Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PIC1 Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07456371 ↗ |
| Modality | Cell therapy | “in vivo generated Chimeric Antigen Receptor T-cell (CAR-T) therapy” NCT07456371 ↗ |
| Route | Intravenous | “subjects will receive an intravenous infusion of PIC1 injection designed for in vivo CAR-T generation.” NCT07456371 ↗ |